These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38102772)

  • 1. Toward an improved understanding of hypomethylating agent and venetoclax therapies.
    DiNardo CD
    Am J Hematol; 2024 Feb; 99(2):152-154. PubMed ID: 38102772
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
    Bouligny IM; Murray G; Ho T; Doyel M; Patel T; Boron J; Tran V; Gor J; Hang Y; Alnimer Y; Zacholski K; Venn C; Wages NA; Grant S; Maher KR
    Leuk Res; 2023 Nov; 134():107370. PubMed ID: 37659346
    [No Abstract]   [Full Text] [Related]  

  • 4. Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
    Niscola P; Gianfelici V; Giovannini M; Piccioni D; Mazzone C; Fabritiis P
    Ann Hematol; 2024 May; 103(5):1787-1788. PubMed ID: 38459155
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
    Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
    J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia.
    Candoni A
    Lancet Haematol; 2024 Apr; 11(4):e245-e246. PubMed ID: 38452789
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.
    Shoumariyeh K; Jung J; Rassner M; Dold SM; Riebl V; Pantic M; Herget G; Marks R; Lübbert M; Wäsch R; Engelhardt M
    Ann Hematol; 2021 Jun; 100(6):1637-1640. PubMed ID: 33712868
    [No Abstract]   [Full Text] [Related]  

  • 8. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
    Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
    Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
    Mei M; Aldoss I; Marcucci G; Pullarkat V
    Am J Hematol; 2019 Mar; 94(3):358-362. PubMed ID: 30499168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
    Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
    Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
    Venugopal S; Maiti A; DiNardo CD; Qiao W; Ning J; Loghavi S; Daver NG; Kadia TM; Rausch CR; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Ravandi F; Kantarjian HM; Konopleva MY
    Leuk Lymphoma; 2021 Dec; 62(14):3501-3505. PubMed ID: 34474640
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen.
    Ohmoto A; Fuji S
    Expert Rev Hematol; 2023; 16(10):761-771. PubMed ID: 37670667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
    Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
    Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
    [No Abstract]   [Full Text] [Related]  

  • 14. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
    Othman TA; Tenold ME; Moskoff BN; Azenkot T; Jonas BA
    Expert Rev Hematol; 2021 May; 14(5):407-417. PubMed ID: 34076549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
    Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
    [No Abstract]   [Full Text] [Related]  

  • 16. BCL-2 inhibition in AML: an unexpected bonus?
    Konopleva M; Letai A
    Blood; 2018 Sep; 132(10):1007-1012. PubMed ID: 30037885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A.
    Pratz KW; DiNardo CD; Selleslag D; Li J; Yamamoto K; Konopleva M; Stevens D; Kantarjian H; Traina F; Venditti A; Mayer J; Montez M; Jin H; Duan Y; Brackman D; Zha J; Potluri J; Werner M; Jonas BA
    Am J Hematol; 2022 Nov; 97(11):E416-E419. PubMed ID: 36054316
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.
    Gruszczynska A; Maiti A; Miller CA; Ramakrishnan SM; Link DC; Uy GL; Petti AA; Hayes K; DiNardo CD; Ravandi F; Ley TJ; Spencer DH; Gao F; Konopleva MY; Welch JS
    Haematologica; 2024 Aug; 109(8):2653-2659. PubMed ID: 38618679
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.
    Niswander LM; Chung P; Diorio C; Tasian SK
    Haematologica; 2023 Nov; 108(11):3142-3147. PubMed ID: 37021525
    [No Abstract]   [Full Text] [Related]  

  • 20. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.